Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells

Sorafenib is currently used to treat advanced and/or unresectable hepatocellular carcinoma (HCC), but the increase of the median survival was only 3 months. Moreover, sorafenib has severe side effects and patients develop resistance quickly. Epigenetic alterations such as DNA methylation play a deci...

Descripción completa

Detalles Bibliográficos
Autores principales: Abeni, Edoardo, Salvi, Alessandro, Marchina, Eleonora, Traversa, Michele, Arici, Bruna, De Petro, Giuseppina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467784/
https://www.ncbi.nlm.nih.gov/pubmed/28560380
http://dx.doi.org/10.3892/ijo.2017.4019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467784/
https://www.ncbi.nlm.nih.gov/pubmed/28560380
http://dx.doi.org/10.3892/ijo.2017.4019

Ejemplares similares